APA

Sfiridaki A., Miyakis S., Tsirakis G., Alegakis A., Passam A. M., Kandidaki E., Margioris A. N. & Alexandrakis M. G. (20051206). Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. : Clinical chemistry and laboratory medicine.

Chicago

Sfiridaki Aikaterini, Miyakis Spiros, Tsirakis George, Alegakis Athanassios, Passam Andreas M, Kandidaki Ermioni, Margioris Andrew N and Alexandrakis Michael G. 20051206. Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. : Clinical chemistry and laboratory medicine.

Harvard

Sfiridaki A., Miyakis S., Tsirakis G., Alegakis A., Passam A. M., Kandidaki E., Margioris A. N. and Alexandrakis M. G. (20051206). Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. : Clinical chemistry and laboratory medicine.

MLA

Sfiridaki Aikaterini, Miyakis Spiros, Tsirakis George, Alegakis Athanassios, Passam Andreas M, Kandidaki Ermioni, Margioris Andrew N and Alexandrakis Michael G. Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. : Clinical chemistry and laboratory medicine. 20051206.